BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 18038486)

  • 1. Issuance of multiple prescriptions for schedule II controlled substances. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2007 Nov; 72(222):64921-30. PubMed ID: 18038486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes to patient limitation for dispensing or prescribing approved narcotic controlled substances for maintenance or detoxification treatment by qualified individual practitioners. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2008 May; 73(100):29685-8. PubMed ID: 18605404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescriptions for Schedule II controlled substances: Drug Enforcement Administration, Justice. Notice of proposed rulemaking.
    Fed Regist; 1980 Apr; 45(70):24199-200. PubMed ID: 10246081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescriptions; dispensing controlled substances in institutional practitioner emergency rooms--Drug Enforcement Administration, Justice. Withdrawal of proposed rule.
    Fed Regist; 1983 Jun; 48(125):29713-4. PubMed ID: 10261481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allowing central fill pharmacies and retail pharmacies to fill prescriptions for controlled substances on behalf of retail pharmacies. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2003 Jun; 68(121):37405-11. PubMed ID: 12836645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DEA issues proposed rule on e-prescribing.
    Ball FR
    J Med Pract Manage; 2009; 24(4):243. PubMed ID: 19288650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescriptions; requirements clarification--Drug Enforcement Administration (DEA). Final rule.
    Fed Regist; 1991 Jun; 56(106):25025-7. PubMed ID: 10111144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Authority for practitioners to dispense or prescribe approved narcotic controlled substances for maintenance or detoxification treatment. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2005 Jun; 70(120):36338-44. PubMed ID: 15973789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schedules of controlled substances: placement of Zopiclone into schedule IV. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2005 Apr; 70(63):16935-7. PubMed ID: 15806735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definition of "positional isomer" as it pertains to the control of schedule I controlled substances. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2007 Dec; 72(231):67850-2. PubMed ID: 18064769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of immediate precursor used in the illicit manufacture of fentanyl as a schedule II controlled substance. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2010 Jun; 75(124):37295-9. PubMed ID: 20608285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2002 Oct; 67(194):62354-70. PubMed ID: 12369590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedules of controlled substances: placement of lisdexamfetamine into schedule II. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2007 May; 72(85):24532-4. PubMed ID: 17520775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2004 Mar; 69(53):12794-7. PubMed ID: 15029891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2008 Jul; 73(144):43355-7. PubMed ID: 18949877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facsimile transmission of prescriptions for patients enrolled in hospice programs. Drug Enforcement Administration (DEA), Justice. Final rule.
    Fed Regist; 2001 Jan; 66(8):2214-5. PubMed ID: 11503757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The DEA proposes schedule II substance rule.
    Buchanan BL
    WMJ; 2007 Jul; 106(4):230. PubMed ID: 17844715
    [No Abstract]   [Full Text] [Related]  

  • 18. Dispensing controlled substances in institutional practitioner emergency rooms--Drug Enforcement Administration. Notice of proposed rulemaking.
    Fed Regist; 1982 Sep; 47(181):41140. PubMed ID: 10262071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Information on foreign chain of distribution for ephedrine, pseudoephedrine, and phenylpropanolamine. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2010 Mar; 75(43):10168-72. PubMed ID: 20383917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schedules of controlled substances: placement of tapentadol into schedule II. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2009 May; 74(97):23790-3. PubMed ID: 19507329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.